Amikacin was evaluated in vitro against S aureus and a variety of gram negative bacilli. In concentrations of 12.5 μg/ml or less, it suppressed the growth of all organisms except 15% of Proteus mirabilis. Peak serum levels in patients, following a 7.5 mg/kg IM dose, averaged 21 μg/ml at one hour. Most of the drug appeared in the urine during the first six hours after administration. Of six patients receiving an adequate course of treatment, all but one were cured. Treatment in that patient also failed with a subsequent course of gentamicin and carbenicillin and he was cured only by extensive surgical excision of the infected bone. One patient developed an asymptomatic high frequency hearing loss. Another patient, who had a staggering gait after each of her first two doses, was withdrawn from the study. The data suggest that amikacin is an effective agent for the treatment of infections caused by susceptible pathogens.
Haas, Erwin J.; Madhavan, T.; Fisher, Evelyn J.; Cox, Frank; Burch, Keith; Quinn, Edward L.; and Nichols, Richard D.
"Amikacin: Clinical and Laboratory Studies,"
Henry Ford Hospital Medical Journal
: Vol. 23
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol23/iss2/3